Today’s Forbes Daily newsletter covers Trump’s Fed chair candidates, Palantir’s rising share price, RFK cancels vaccine funding, GOP pushes for more on Epstein and more.

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca PLC ( NASDAQ: AZN) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET ...

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the ...

Uncertainty about pharmaceutical tariffs continues to loom over the pharmaceutical industry, with some companies committing ...

AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market.

LONDON: British pharmaceutical giant AstraZeneca today said net profit rose 27% in the second quarter, boosted by record growth in its key US market.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Earlier this month, fellow European drugmaker Roche Holding AG said it was looking into direct sales to bypass players like ...

Nihal Sarin: I’m excited for the opportunity. Even though I have competed against these players in other formats, the format at EWC brings a different kind of intensity.

AstraZeneca’s efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease medicines drove total revenue for the second quarter 11% higher to $14.46 ...